In this update, we review the recent discovery of autosomal recessive variants in sorbitol dehydrogenase as one of the commonest and potentially treatable causes of hereditary motor neuropathy and CMT2. We also report on recent therapeutic advances in hereditary neuropathy including the use of lipid nanoparticle sequestered antisense oligonucleotides in CMT1A and lipid nanoparticle delivered CRISPR-Cas9 gene editing in ATTR amyloidosis.
Keywords: ATTR amyloidosis; Charcot–Marie–tooth disease; PMP22 gene silencing; SORD-associated CMT; SPTLC1-associated HSN1.
© 2022. The Author(s).